Deal strengthens CNS portfolio and ensures continuity of access for MS patients

Three-year trial results reveal long-term improvements in pain and lesion resolution

New self-loading reagents offer unmatched flexibility for immunologists

First-in-class mast cell selective c-Kit inhibitor enters clinical testing in Germany

SBT-77-7101 shows favourable safety and early signs of efficacy in patients with refractory RA

Faster scans and same-day results improve patient experience across community sites

New data support European filing for nonsteroidal topical treatment

Domain Therapeutics has announced the first patients have been dosed in its phase 1/2 DOMISOL clinical trial of […]

$25m milestone payment supports pipeline progress in neurodegenerative disease research

Qureight’s imaging platform validated in peer-reviewed study